FDA Is Listening: Adolor Cited For Downplaying REMS At Conference

A company representative's oral statement that the REMS for the gastrointestinal surgery recovery drug Entereg is "due to logistics" was unacceptable, DDMAC letter says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet